DOI: http://dx.doi.org/10.18203/2349-2902.isj20203789

A comparative clinical evaluation of outcome of medical and surgical management of symptoms due to benign prostatic hyperplasia

Bhushan Kumar Gnana, Sanjeeva Rao Matlapudi

Abstract


Background: Benign hypertrophy of prostate is common disorder and benign neoplasm of man above 50 years of age. Around 30% patients with benign hypertrophy of prostate lower urinary tract symptoms (LUTS) but all symptoms may not be due to benign hypertrophy of prostate (BHP). Present study has been designed for comparative evaluation of the outcome of medical and surgical management of symptoms, due to benign prostatic hyperplasia by using IPSS (international prostate score) and quality of life score as tool.

Methods: In present study patients with LUTS, clinically diagnosed by per rectal digital examination and transrectal ultrasonographically confirmed cases of enlargement of prostate are enrolled for this study. Patients enrolled were divided equally in three groups.

Results: After six month the mean IPSS score in silodosin (Sd) group was 6.55±0.86 and in Sd+Dutasteride (Dt) group it was 5.09±1.12. After six months mean IPSS score in Sd+Dt group was 5.09±1.12 and in TURP group it was 2.44±0.59.

Conclusions:  Single drug treatment with silodosin is associated with slow and less improvement in IPSS score in comparison with silodosin and dutasteride. But the response to TURP was better and faster than medical management.


Keywords


Benign prostatic hyperplasia, TURP, Medical management, Comparison

Full Text:

PDF

References


Epistein JI. The lower urinary tract and male genital system. Robins and Croton, Pathological basis of disease. 8th edition. Amsterdam: Elsevier publication; 2010:994-5.

Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361(9366):1359-67.

Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148-51.

Michalak J, Tzou D, Funk J. HoLEP: the gold standard for the surgical management of BPH in the 21(st) Century. Am J Clin Exp Urol. 2015;3(1):36-42.

Lepor H. Medical treatment of benign prostatic hyperplasia. Rev Urol. 2011;13(1):20-33.

Cambio AJ, Evans CP. Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Ther Clin Risk Manag. 2007;3(1):181-96.

Abraham TK. The International Consultation on Benign Prostatic Hyperplasia. Available at: https://apps.who.int/iris/handle/10665/41818. Accessed on 27 May 2020.

Shah Ak, Srivastava A, Karan SC. Medical management of patients with benign prostatic hyperplasia: A study in Indian population. J Mar Med Soc. 2018;20:104-10.

Huang LK, Chang YH, Shao IH, Lee TL, Hsieh ML. Clinical Outcome of Immediate Transurethral Surgery for Benign Prostate Obstruction Patients with Acute Urinary Retention: More Radical Resection Resulted in Better Voiding Function. J Clin Med. 2019;8(9):1278.

Hagiwara K, Koie T, Iwamura H, Imai A, Hatakeyama S, Yoneyama T, et al. Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a single-arm prospective study. Biomed Res Int. 2016;2016:4975851.

Shi-Wei H, Chung-You T, Chi-Shin T, Ming-Chieh S, Yi-Chun Y, Kuo-Liong C, et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systemic review and network meta-analysis. BMJ. 2019;367:15919.

Macey MR, Raynor MC. Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review. Semin Intervent Radiol. 2016;33(3):217-23.

Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-31.

Zaman Huri H, Hui Xin C, Sulaiman CZ. Drug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective study. PLoS One. 2014;9(1):e86215.

Jiwrajka M, Yaxley W, Ranasinghe S, Perera M, Roberts MJ, Yaxley J. Drugs for benign prostatic hypertrophy. Aust Prescr. 2018;41(5):150-3.